Ardelyx ARDX 深 沪
等待开盘 08-25 09:30:00 美东时间
3.74
-0.150
-3.86%
华盛通- 最 高3.89
- 今 开3.88
- 成交量 521.04万股
- 最 低 3.725
- 昨 收 3.89
- 总市值 9.66亿
- 52周最高 8.40
- 市盈率 静 --
- 换手率 2.02%
- 52周最低 3.725
- 委 比 -16.33%
- 总股本 2.58亿
- 历史最高 35.48
- 量 比 1.43
- 振 幅 4.24%
- 历史最低 0.49
- 每 手 1
- 风险率 0.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1610.53%！Ascendiant Capital上调Alzamend Neuro目标价至26美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Alzamend Neuro"买入"评级，目标价从25美元升至26美元；Tigress Financial：维持Legence"买入"评级，目标价从125美元升至130美元
08-20 08:39
Piper Sandler Maintains Overweight on Ardelyx, Lowers Price Target to $15
Piper Sandler analyst Christopher Raymond maintains Ardelyx (NASDAQ:ARDX) with a Overweight and lowers the price target from $16 to $15.
08-17 23:55
Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)
ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord. NEW YORK, Aug. 13, 2026 ...
08-14 10:44
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
BTIG Maintains Buy on Ardelyx, Lowers Price Target to $14
BTIG analyst Julian Harrison maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price target from $17 to $14.
08-07 21:45
财报速睇 | Ardelyx 2026财年Q2营收1.21亿美元，同比增长23.8%；归母净利润亏损0.17亿美元，同比亏损缩窄12.4%
华盛资讯8月7日讯，Ardelyx公布2026财年Q2业绩，公司Q2营收1.21亿美元，同比增长23.8%，归母净利润亏损0.17亿美元，同比亏损缩窄12.4%。
08-07 10:51
财报速睇 | Ardelyx 2026财年Q2营收1.21亿美元，同比增长23.5%；归母净利润亏损0.17亿美元，同比亏损缩窄10.5%
华盛资讯8月7日讯，Ardelyx公布2026财年Q2业绩，公司Q2营收1.21亿美元，同比增长23.5%，归母净利润亏损0.17亿美元，同比亏损缩窄10.5%。
08-07 07:07
Ardelyx shares are trading lower after the company reported worse-than-expected Q2 financial results.
Ardelyx shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-07 04:49
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
Monopar Therapeutics Inc. has appointed seasoned commercial leaders to support the anticipated launch of its first product, ALXN1840, for Wilson disease, pending FDA approval. Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, has joined the Board of Directors. Sharon Funk and Daniel Olmstead have been appointed as Senior Vice Presidents for Sales and Marketing, and Market Access, Distribution, and Patient Services, respe...
07-20 12:00
